| Name | Title | Contact Details |
|---|
LifeLine Financial captains fast-growing businesses nationwide in service, technology, retail, and trades. We offer exceptional bookkeeping and accounting services nationwide. Call us today and grab a LifeLine (603) 782-4663
We are automotive company.
MotoRad Ltd. is a global manufacturer of automotive components, specializing in thermal management systems. Established in 1958 and originally known as Fishman Engineering Ltd., the company is now owned by Fortissimo Investment Funds and employs 156 people. In 2025, MotoRad reported an annual revenue of $28.7 million, with Matt Buchholz serving as CEO. The company develops and manufactures a range of thermal management solutions, including thermostats, caps, and sensors. These products are designed for internal combustion engines, hybrid vehicles, plug-in hybrids, and battery electric vehicles. MotoRad serves automotive OEMs, aftermarket distributors, and industrial applications, ensuring a high level of product availability and a 97.81% global fill rate to meet customer needs. The company emphasizes innovation and collaborative work environments, focusing on employee development and technological advancement.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.